Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo
Authors
Keywords
-
Journal
Scientific Reports
Volume 5, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-08-04
DOI
10.1038/srep12853
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hypericin suppresses osteoclast formation and wear particle-induced osteolysis via modulating ERK signalling pathway
- (2014) Zhengxiao Ouyang et al. BIOCHEMICAL PHARMACOLOGY
- The role of MAPK signalling pathways in the response to endoplasmic reticulum stress
- (2014) Nicola J. Darling et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling
- (2014) Zanjing Zhai et al. BREAST CANCER RESEARCH AND TREATMENT
- Upregulation of Tumor Necrosis Factor α and ADAMTS-5, But Not ADAMTS-4, in Human Intervertebral Cartilage Endplate With Modic Changes
- (2014) Shuai Chen et al. SPINE
- A review of denosumab for the treatment of osteoporosis
- (2014) Tsuyoshi Miyazaki et al. Patient Preference and Adherence
- Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades
- (2013) Xinhua Qu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Andrographolide suppresses RANKL-induced osteoclastogenesisin vitroand prevents inflammatory bone lossin vivo
- (2013) Z J Zhai et al. BRITISH JOURNAL OF PHARMACOLOGY
- Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?
- (2013) E. Verron et al. DRUG DISCOVERY TODAY
- Lycorine hydrochloride selectively inhibits human ovarian cancer cell proliferation and tumor neovascularization with very low toxicity
- (2013) Zhifei Cao et al. TOXICOLOGY LETTERS
- Cost–effectiveness of denosumab in the treatment of postmenopausal osteoporotic women
- (2013) Mickaël Hiligsmann et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition
- (2012) Lv Li et al. Cancer Cell International
- Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry
- (2012) Ruifang Liu et al. Pigment Cell & Melanoma Research
- Prevention of Wear Particle-Induced Osteolysis by a Novel V-ATPase Inhibitor Saliphenylhalamide through Inhibition of Osteoclast Bone Resorption
- (2012) An Qin et al. PLoS One
- Evaluation of analgesic, anti-inflammatory and hepatoprotective effects of lycorine from Sternbergia fisheriana (Herbert) Rupr.
- (2011) G. Saltan Çitoğlu et al. FITOTERAPIA
- Lycorine inhibits lipopolysaccharide-induced iNOS and COX-2 up-regulation in RAW264.7 cells through suppressing P38 and STATs activation and increases the survival rate of mice after LPS challenge
- (2011) Jingjing Kang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication
- (2011) Jiangning Liu et al. Virology Journal
- Denosumab
- (2010) René Rizzoli et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-osteoporotic constituents from Indian medicinal plants
- (2010) Manmeet Kumar et al. PHYTOMEDICINE
- New lycorine-type alkaloid from Lycoris traubii and evaluation of antitrypanosomal and antimalarial activities of lycorine derivatives
- (2008) Yosuke Toriizuka et al. BIOORGANIC & MEDICINAL CHEMISTRY
- LPS/TLR4 signal transduction pathway
- (2008) Yong-Chen Lu et al. CYTOKINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started